The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of multiple sclerosis with the use of a therapeutic product developed from mesenchymal stromal cells.
As the first clinical trials ever to be conducted in the U.S. with embryonic stem cells are about to commence, FDA regulators convene a special meeting to debate the inherent risks and dangers.
The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of ischemic stroke with the use of a therapeutic product developed from mesenchymal stromal cells.
Scientists, doctors, patients and lawmakers work together to draft a state law that would expedite the storage and therapeutic administration of umbilical cord blood stem cells.
The discovery of mesenchymal stem cells in the eye has vast implications.
Stem Cells derived from umbilical cord blood are found to slow the progression of Alzheimer’s disease in mice.
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2025, Stem Cell Insitute Panama. All rights reserved.